Experimental graft arteriosclerosis

DH Adams, NL Tilney, JJ Collins Jr… - Transplantation, 1992 - journals.lww.com
DH Adams, NL Tilney, JJ Collins Jr, MJ Karnovsky
Transplantation, 1992journals.lww.com
Progressive graft arteriosclerosis is responsible for the majority of late deaths occurring in
cardiac transplant recipients. In order to define a model of this disease in the rat, we
exchanged heterotopic cardiac allografts between MHC-compatible inbred strains. Lewis
rats served as donors and F-344 rats as recipients. Twenty allografts were followed by daily
palpation and removed at the time of terminal rejection or on the 120th post-operative day
for pathologic study. Sixteen allografts (80%) survived at least three weeks, and five …
Abstract
Progressive graft arteriosclerosis is responsible for the majority of late deaths occurring in cardiac transplant recipients. In order to define a model of this disease in the rat, we exchanged heterotopic cardiac allografts between MHC-compatible inbred strains. Lewis rats served as donors and F-344 rats as recipients. Twenty allografts were followed by daily palpation and removed at the time of terminal rejection or on the 120th post-operative day for pathologic study. Sixteen allografts (80%) survived at least three weeks, and five allografts (25%) survived indefinitely. The majority of arteries (greater than 90%) examined demonstrated significant intimal disease; histologic findings in lesions in allografts rejecting at early time points included intense mononuclear cell infiltration of the intima, while lesions in long-term-surviving allografts demonstrated fibrous intimal thickening, which is characteristic of graft arteriosclerosis seen clinically. A limited course of cyclosporine therapy in F-344 recipients increased the incidence of indefinite allograft survival from 25% to 86%, and was associated with a modest reduction in the amount of intimal disease observed. These results suggest that this model should be useful in future studies regarding the pathogenesis and therapy of cardiac graft arteriosclerosis.
Lippincott Williams & Wilkins